LimmaTech Biologics Secures $3M in Initial Phase of Funding

LimmaTech Biologics has declared the conclusion of the second round in its initial funding, obtaining an extra $3 million from a novel contributor, Tenmile, for the advancement of vaccine technology. 

The contribution will be utilized by the firm to progress its self-stimulating and multi-antigen vaccine technology project. 

The firm’s dedication to tackling perilous infections is emphasized by initiatives aimed at staphylococcus aureus, STDs, and shigella. 

LimmaTech is applying its vaccine framework alongside disease-specific vaccine strategies to hinder microbial infections that are getting progressively more challenging to manage. 

Dr Franz-Werner, the head executive at Limmatech, commented, “With LimmaTech’s robust and expanding pipeline of innovative vaccine candidates we are pursuing a technology-agnostic approach to provide the most effective, disease-specific vaccines for combating severe pathogens that are increasingly resistant to antibiotics.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.